Frauke Zipp
Professor of Neurology
Johannes Gutenberg University Medical Center Mainz

Research Profile

After studying Medicine in Germany, the USA, Canada and England, Frauke Zipp began her scientific career at the MPI Martinsried with Hartmut Wekerle in Neuroimmunology. During clinical training with Johannes Dichgans in Tübingen, she was a visiting scientist at the NIH. After a decade at the Charité, she is currently Director of the Department of Neurology at the University Medical Center Mainz. She is spokesperson of a Collaborative Research Center on Multiple Sclerosis, Executive Board Member of the Competence Network of Multiple Sclerosis (KKNMS), Council Member of ECTRIMS and Board Member of the International Society of Neuroimmunology (ISNI) as well as Conference Chair of ISNI in 2014 in Germany. Frauke Zipp performed several IITs, contributed to a large series of clinical trials and participated in steering as well as data monitoring committees of clinical trials.

General Information

Name:	Frauke Zipp, Prof. Dr. med.
Address:	Department of Neurology Johannes Gutenberg University Mainz Langenbeckstr. 1, 55131 Mainz Tel.: +49-6131-17 7156 Fax: +49-6131-17 5697 E-mail: frauke.zipp@unimedizin-mainz.de Homepage: http://www.unimedizin-mainz.de/neurologie/
Position:	Director of the Department of Neurology

Education

1982 – 1989	Medicine, J.W. Goethe University, Frankfurt, Germany; Studies in North America (North Carolina; Toronto) and England (Royal Free, London)
1989 – 1992	Residency in Neurology, J.W. Goethe Univ., Frankfurt (Prof. Fischer)

Degrees and awards

1986 – 1990	Medical thesis (Dr. med.), Anatomy, J.W. Goethe Univ., Frankfurt, Prof. M. Frotscher
1998	Langheinrich-Preis for MS Research
1999	Research Prize from the DCP Akademie for Clinical Diagnosis
2003	Nils-Ilja-Richter Preis for Lancet work 2003

2005	Pette-Prize from the Society of Neurology Germany
2011	Alexander Karl Prize
2011	Member German National Academy of Sciences Leopoldina

Professional Experience

1993 – 1995	Postdoctoral Fellow, Dept. of Neuroimmunology, Max Planck Institute, Martinsried, Germany (*Profs. H. Wekerle and R. Hohlfeld)*
1995 – 1998	Fellowship and "Habilitation" in Neurology, Department of Neurology at Eberhard Karls University, Tübingen, Germany, *Prof. J. Dichgans*
1996	Visiting Scientist, National Institute of Health, Division of Neuroimmunology, Bethesda, MD, USA, *Prof. H. McFarland*
1998	Full Boards in Neurology April 1998
1998 – 2002	Senior Physician, Dept. of Neurology, Charité, Berlin
2002 - 2006	C3-Professor; Head of the Institute of Neuroimmunology, Charité, Berlin, Research Section at Campus Mitte and Clinic at Campus Buch
2006- 2009	W3-Professor (Full Professor) at the Charité - University Hospital Berlin; and Clinical Coordinator and Board Director at the Max-Delbrück-Center for Molecular Medicine (Helmholtz); Director of the Cecilie-Vogt-Klinik, Charité
2006-2009 (move)	Spokesperson of GRK 1258 "Influence of inflammation on nervous system function"
2007-2009 (move)	Board Director of the Excellence Cluster "NeuroCure" and Participant in the Graduate School of Excellence for Regenerative Therapy (BSRT)
2008-2009 (move)	Spokesperson of the Transregio CRC TR 43 "The brain as a target of inflammatory processes"
Since 2009	W3-Professor (Full Professor) for Neurology and Director of the Department of Neurology, University Medical Center Mainz, Johannes Gutenberg University Mainz
Since 2012	Spokesperson of the Collaborative Research Center on Multiple Sclerosis CRC TR 128 (German Research Council DFG)

Other professional activities

Member of the Medical Advisory Board of the German Multiple Sclerosis Society;
Member of the Executive Board of the Rheinland Pfalz Multiple Sclerosis Society;
Member of ECTRIMS Council;
Member of the Gutenberg-Forschungs-Kolleg;
Executive Board Member of the Kompetenznetz Multiple Sklerose (KKNMS, Ministry of Science BMBF);
Member of Board of the International Society of Neuroimmunology (ISNI);
Member of the International Advisory Boards of the Institute for Brain and Spinal Cord Diseases of the University Hospital Pitié-Salpetrière, Paris
Member of the Multiple Sclerosis International Federation (MSIF)

SELECTED PUBLICATIONS

Zipp F, Gold R, Wiendl H. 2013. Identification of inflammatory neuronal injury and prevention of neuronal damage in Multiple Sclerosis – hope for novel therapies? **JAMA Neurol**, in press

Liblau R, Gonzalez-Dunia D, Wiendl H, Zipp F. 2013. Neurons as targets for T cells in the nervous system. **Trends Neurosci** 36:315-324

IMSGC, last and corresponding author: Zipp F. 2013. MANBA, CXR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. **Brain** 136:1778-82

Methner A, Zipp F. 2013. Multiple Sclerosis in 2012: Novel therapeutic options and drug targets in MS. **Nat Rev Neurol** 9:72-3

Jolivel V, Luessi F, Masri J, Kraus S, Hubo M, Poisa-Beiro L, Klebow S, Paterka M, Yogev N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F§, Waisman A§. 2013. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating Multiple Sclerosis. **Brain** 136:1048-66

Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. 2012. The problems and promises of research into human immunology and autoimmune disease. **Nature Med** 18: 48-53.

Siffrin, V, Radbruch H, Glumm R, Niesner R, Paterka M, Herz J, Leuenberger T, Lehmann SM, Luenstedt S, Rinnenthal JL, Laube G, Luche H, Lehnardt S, Fehling H, Griesbeck O, Zipp F. 2010. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. **Immunity** 33: 424-436.
Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. 2010. Multiple sclerosis -candidate mechanisms underlying CNS atrophy. **Trends Neurosci** 33: 202-10

Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, Bendix I, Ifergan I, Schadock I, Mori MA, Van Horssen J, Schröter F, Han MH, Bader M, Steinman L, Aktas O, Zipp F. 2009. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. **Nature Med** 15: 788-793

Siffrin V, Brandt AU, Radbruch H, Herz J, Boldakowa N, Leuenberger T, Werr J, Hahner A, Schulze-Topphoff U, Nitsch R, Zipp F. 2009. Differential immune cell dynamics in the CNS cause CD4+ T cell compartmentalization. **Brain** 132: 1247-58

Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schröter F, Niemann O, Siegert E, Bendix I, Brüstle O, Nitsch R, Zipp F§, Aktas O§. 2008. Sirt1 critically contributes to the redox-dependent fate of neural progenitors. **Nature Cell Biol** 10: 385-394 §equally contributing

Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig HP, Hohlfeld R, Vincent A, Zipp F. 2007.

Antibody to Aquaporin-4 in the Diagnosis of Neuromyelitis Optica. **PLoS Med** 4: 669-674

Hoffmann O, Priller J, Prozorovski T, Schulze-Topphoff U, Baeva N, Lunemann JD, Aktas O, Mahrhofer C, Stricker S, Zipp F[§], Weber JR[§]. 2007. TRAIL limits excessive host immune responses in bacterial meningitis. **J Clin Invest** 117: 2004–2013
[§]equally contributing

Zipp F, Aktas O. 2006. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. **Trends Neurosci** 29: 518-527

Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Prozorovski T, Meier S, Osmanova V, Kwidzinski E, Pohl E, Beyer M, Bechmann I, Nitsch R, Zipp F. 2005. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. **Neuron** 46: 421-432

Wandinger KP, Lünemann J, Wengert O, Bellmann-Strobel J, Aktas O, Weber A, Grundström E, Ehrlich E, Wernecke KD, Volk HD, Zipp F. 2003. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for IFN-beta therapy in multiple sclerosis. **The Lancet** 361, 2036-2043

Aktas O, Waiczies S, Smorodchenko A, Dörr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th 1 cells through atorvastatin. **J Exp Med** 197, 711-723

Diestel A, Aktas O, Hackel D, Häke I, Meier S, Raine CS, Nitsch R[§], Zipp F[§], Ullrich O[§]. 2003. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. **J Exp Med** 198: 1729-1740[§]equally contributing

Zipp, F, Weil JG, Einhäupl KM. 1999. No evidence for increased demyelinating diseases induced by hepatitis B vaccination. **Nature Med**, 5, 964-965